Original Article
Messenger RNA for FOXP3 in the Urine of Renal-Allograft Recipients
N Engl J Med 2005; 353:2342-2351December 1, 2005
- Abstract
Background
The outcome of renal transplantation after an episode of acute rejection is difficult to predict, even with an allograft biopsy.
Methods
We studied urine specimens from 36 subjects with acute rejection, 18 subjects with chronic allograft nephropathy, and 29 subjects with normal biopsy results. Levels of messenger RNA (mRNA) for FOXP3, a specification and functional factor for regulatory T lymphocytes, and mRNA for CD25, CD3ε, perforin, and 18S ribosomal RNA (rRNA) were measured with a kinetic, quantitative polymerase-chain-reaction assay. We examined associations of mRNA levels with acute rejection, rejection reversal, and graft failure.
Results
The log-transformed mean (±SE) ratio of FOXP3 mRNA copies to 18S ribosomal RNA copies was higher in urine from the group with acute rejection (3.8±0.5) than in the group with chronic allograft nephropathy (1.3±0.7) or the group with normal biopsy results (1.6±0.4) (P<0.001 by the Kruskal–Wallis test). FOXP3 mRNA levels were inversely correlated with serum creatinine levels measured at the time of biopsy in the acute-rejection group (Spearman's correlation coefficient = –0.38, P=0.02) but not in the group with chronic allograft nephropathy or the group with normal biopsy results. Analyses of receiver-operating-characteristic curves demonstrated that reversal of acute rejection can be predicted with 90 percent sensitivity and 73 percent specificity with use of the optimal identified cutoff for FOXP3 mRNA of 3.46 (P=0.001). FOXP3 mRNA levels identified subjects at risk for graft failure within six months after the incident episode of acute rejection (relative risk for the lowest third of FOXP3 mRNA levels, 6; P=0.02). None of the other mRNA levels were predictive of reversal of acute rejection or graft failure.
Conclusions
Measurement of FOXP3 mRNA in urine may offer a noninvasive means of improving the prediction of outcome of acute rejection of renal transplants.
Media in This Article
Figure 1
Levels of FOXP3 mRNA in Urinary Cells.Figure 2
Correlation between Levels of FOXP3 mRNA in Urinary Cells and Reversal of an Episode of Acute Rejection.Article Activity
- Article
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD), but a shortage of organs limits its availability.1 Renal-allograft failure is the fourth most common cause of ESRD in the United States2 and contributes to the shortage of organs.
Acute rejection is an important risk factor for allograft failure.3-6 The current approach to treatment of acute rejection is uniform, although it is well recognized that some rejection episodes are not fully reversible and lead to long-term graft dysfunction and failure, whereas others are easily treatable and benign.6 The outcome of acute rejection is difficult to predict, and histologic features that are observed in allograft tissue obtained by core needle biopsy are currently the best predictors.7,8 The invasive procedure of allograft biopsy, however, is associated with complications such as bleeding, arteriovenous fistula, and even graft loss.9,10
We previously reported a method using a quantitative polymerase chain reaction (PCR) to measure messenger RNA (mRNA) levels of immune products within urinary cells of renal-transplant recipients.11-13 This noninvasive and nucleic acid–based technique allows for the early diagnosis of acute rejection by detection of increased levels of cytolytic T-cell products such as granzyme B and perforin,11 integrins such as CD103,12 and key chemokine and chemokine-receptor combinations such as gamma-inducible protein of 10kD (IP-10) and its receptor, CXCR3, which promote effector T-cell recruitment to a transplant.13
Recent studies have highlighted the role of a specialized subgroup of CD4+CD25+ T lymphocytes, termed regulatory T lymphocytes (Treg cells), in the suppression of autoimmunity.14,15 Treg cells specifically express the X-linked forkhead/winged helix transcription factor, FOXP3,16 and mutations in the human FOXP3 gene result in an autoimmune disease characterized by polyendocrinopathy and enteropathy that is fatal in infancy.17,18 In a similar manner, male mice with a loss-of-function mutation in the Foxp3 gene (scurfy mice) or with a deficiency of the Foxp3 gene generated by homologous recombination waste away and die within three to four weeks of life with multiorgan lymphocytic infiltrates; transfer of the Foxp3 gene reverses this process.16,19,20
In view of the dominant role of Treg cells in the maintenance of self-tolerance14,15 and in view of the cells' suppressive role in experimental models of transplantation tolerance,21-23 we reasoned that measurement of FOXP3 mRNA levels in urinary cells might provide insight into the immunologic events within a renal allograft undergoing acute rejection. We developed a kinetic, quantitative PCR assay and demonstrate that levels of FOXP3 mRNA in urinary cells predict the reversibility of acute rejection and identify patients at high risk for graft loss after an episode of acute rejection.
Methods
Study Cohorts
We examined urine samples from 83 kidney-transplant recipients. In this group were 36 subjects with graft dysfunction (mean [±SD] creatinine level, 3.6±2.4 mg per deciliter [318.2±212.2 μmol per liter]) and biopsy-confirmed acute rejection (mean age, 41±12 years; 15 men and 21 women; 13 white, 12 black, and 11 with other racial or ethnic backgrounds; with 20 living and 16 deceased donors), 29 subjects with stable allograft function (mean creatinine level, 1.4±0.4 mg per deciliter [123.8±35.4 μmol per liter]) and normal allograft biopsy (mean age, 44±14 years; 15 men and 14 women; 12 white, 4 black, and 13 with other racial or ethnic backgrounds; with 26 living and 3 deceased donors), and 18 subjects with allograft dysfunction (mean creatinine level, 3.1±1.6 mg per deciliter [274.0±141.4 μmol per liter]) and biopsies classified as indicating chronic allograft nephropathy (mean age, 52±12 years; 9 men and 9 women; 9 white, 2 black, and 7 with other racial or ethnic backgrounds; with 5 living and 13 deceased donors).
Seventy-five of the 83 urine specimens were collected before the biopsy procedure, and 8 samples were obtained after the procedure. Formalin-fixed, paraffin-embedded renal-biopsy specimens were stained with hematoxylin and eosin, periodic acid–Schiff, and Masson's trichrome stains and were scored with the use of the Banff 97 classification24 by a pathologist who was blinded to the results of molecular studies. Immunosuppression consisted of a calcineurin inhibitor–based regimen (cyclosporine or tacrolimus), with the administration of glucocorticoids, antilymphocyte antibodies (muromonab-CD3 [OKT3] or antithymocyte globulin), or both for the treatment of acute rejection.11 The study was approved by the institutional review board at the Weill Medical College of Cornell University in New York, and each patient gave written informed consent.
Quantitation of mRNA by Kinetic, Quantitative PCR
Total RNA was isolated from urine-cell pellets, quantified and reverse transcribed to complementary DNA (cDNA).11 We designed and synthesized oligonucleotide primers and fluorogenic probes for the measurement of mRNA levels of FOXP3, CD25, CD3ε, perforin, and 18S ribosomal RNA (rRNA) (Table 1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org). PCR analysis was performed by a two-step process, a preamplification step followed by measurement of mRNA with an ABI Prism 7700 system (the PCR protocol is provided in the Supplementary Appendix). Transcript levels were calculated by a standard curve method,12 and mRNA copy numbers were normalized with the use of 18S rRNA copy numbers (the number of mRNA copies in 1 μg of RNA divided by the number of 18S rRNA copies in 1 fg of RNA). When no detectable level of a transcript was found, a value equal to half the minimum observed 18S-normalized level was assigned. For an estimation of group means, this method is considered a reasonable substitute for the value of zero or the minimum detected value; moreover, the nonparametric statistical tests of group differences reported below are not affected by the choice of value.25
Statistical Analysis
The levels of mRNA for FOXP3, CD25, CD3ε, perforin, and 18S rRNA deviated from a normal distribution (P<0.001), but a log transformation substantially reduced the positive skew. We used the 18S-normalized level as the dependent variable in a Kruskal–Wallis test to identify any differences among the group with acute rejection, the group with chronic allograft nephropathy, and the group with normal biopsy results and then used Dunn's test for multiple comparisons. The Mann–Whitney test, equivalent to the Kruskal–Wallis test when applied to two groups, was used when mRNA levels were compared between two groups. Spearman's rank-order correlations were used to test for a monotonic association of the 18S-adjusted mRNA transcript levels with serum creatinine levels and time (in days) from kidney transplantation to biopsy. An episode of acute rejection was classified as reversible if the serum creatinine level returned to within 15 percent of the prerejection level within four weeks after the initiation of antirejection treatment. A second end point was the loss of the graft during the first six months after the diagnosis of acute rejection. We used receiver-operating-characteristic (ROC) curves to analyze mRNA levels in order to determine the cutoff points that yielded the highest combined sensitivity and specificity for predicting the outcome of an episode of acute rejection.
Results
Levels of FOXP3 mRNA in Urinary Cells
The log-transformed mean (±SE) ratio of FOXP3 mRNA copies to 18S-rRNA copies in urinary cells was 3.8±0.5 in the 36 subjects with acute rejection and was higher than the levels in both the 18 subjects with chronic allograft nephropathy (1.3±0.7) and the 29 subjects with normal biopsy results (1.6±0.4, P<0.001 by the Kruskal–Wallis test) (Figure 1AFigure 1
Levels of FOXP3 mRNA in Urinary Cells.). Among the three groups, the 18S-normalized, log-transformed mRNA levels of CD25 (6.9±0.4, 4.0±0.5, and 2.8±0.6, respectively; P<0.001), CD3ε (8.2±0.4, 4.3±0.5, and 1.6±0.5; P<0.001), and perforin (7.6±0.4, 4.5±0.4, and 2.8±0.4; P<0.001) were also highest in the acute-rejection cohort (Figure 1B, Figure 1C, and Figure 1D).FOXP3 mRNA Levels and Disease Severity
We observed a significant inverse relationship between the levels of FOXP3 mRNA and serum creatinine measured during an episode of acute rejection (Spearman's correlation coefficient [rs]=–0.38, P=0.02). By contrast, serum creatinine levels were not significantly related to mRNA levels of CD25 (rs=–0.01, P=0.93), CD3ε (rs=–0.11, P=0.54), or perforin (rs=–0.23, P=0.18) in the acute-rejection group. Also, the mean (±SE) serum creatinine level in the 16 subjects with acute rejection of Banff grade IA (moderate tubulitis) did not differ significantly from that of the 20 subjects with grade IB (severe tubulitis) or more (3.3±0.6 mg per deciliter [291.7±53.0 μmol per liter] as compared with 3.8±0.6 mg per deciliter [318.2±53.0 μmol per liter], P=0.57).
There was no correlation between the levels of FOXP3 mRNA and serum creatinine that were measured in the group with chronic allograft nephropathy (rs=0.02, P=0.93) or the group with normal biopsy results (rs=–0.08, P=0.67).
FOXP3 mRNA Levels and Reversal of Acute Rejection
Twenty-six of the 36 episodes of acute rejection qualified as successfully reversed; the remaining 10 did not. Levels of FOXP3 mRNA in urinary cells were significantly higher in the group with successful reversal than in the group without reversal (mean [±SE] level, 4.7±0.5 and 1.5±0.7, respectively; P=0.001) (Figure 2AFigure 2
Correlation between Levels of FOXP3 mRNA in Urinary Cells and Reversal of an Episode of Acute Rejection.). In the two groups, the levels of mRNA for CD25 (7.3±0.4 and 6.0±0.9, P=0.22), CD3ε (8.5±0.5 and 7.4±0.8, P=0.35), and perforin (7.8±0.5 and 7.3±0.7, P=0.43) were not informative of outcome (Figure 2B, Figure 2C, and Figure 2D).The ROC curves (Figure 3Figure 3
Receiver-Operating-Characteristic (ROC) Curves for mRNA Levels.) show the fraction of true positive results (sensitivity) and false positive results (1 – specificity) for various cutoff levels of mRNA for FOXP3, CD25, CD3ε, and perforin. The log-transformed threshold that gave the maximal sensitivity and specificity for FOXP3 mRNA was 3.46; using the cutoff value of 3.46 derived from the data, the FOXP3 mRNA level predicted rejection reversal with a sensitivity of 90 percent and a specificity of 73 percent (P=0.001) (Figure 3A). The levels of mRNA for CD25, CD3ε, and perforin were not predictive of reversal of acute rejection (Figure 3B, Figure 3C, and Figure 3D).Successful reversal of acute rejection, as compared with unsuccessful reversal, was not predicted by the subjects' age (mean [±SD], 41±2.2 years and 40±4.6 years, respectively; P=0.68), sex (10 men and 16 women vs. 5 men and 5 women, P=0.71), race (10 white, 6 black, and 10 with other race or ethnic background vs. 3 white, 6 black, and 1 with other race or ethnic background; P=0.08), graft-donor source (15 living and 11 deceased vs. 5 living and 5 deceased, P=0.68), Banff histologic grade (11 with IA and 15 with >IA vs. 5 with IA and 5 with >IA, P=0.68), or initial antirejection treatment (24 with glucocorticoids and 2 with antilymphocyte antibodies vs. 7 with glucocorticoids and 3 with antilymphocyte antibodies, P=0.12). Among subjects with successful reversal, as compared with those with unsuccessful reversal, serum creatinine levels (median levels, 2.3 mg per deciliter and 6.5 mg per deciliter, respectively; P<0.001) and the time from kidney transplantation to the development of acute rejection (median time, 82 days and 523 days, respectively; P=0.008) were lower. In logistic-regression analyses predicting nonresponse, levels of FOXP3 mRNA in urinary cells remained significant after statistical control for serum creatinine level (P=0.04) and the time from transplantation to rejection (P=0.02).
A linear combination of levels of FOXP3 mRNA and creatinine was a better predictor of rejection reversal (90 percent sensitivity and 96 percent specificity) than FOXP3 mRNA levels alone (90 percent sensitivity and 73 percent specificity) or serum creatinine levels alone (85 percent sensitivity and 90 percent specificity).
FOXP3 mRNA Levels and Allograft Failure
Ten of the 36 subjects with acute rejection lost their grafts within six months after the incident episode of acute rejection, and 9 of those 10 subjects did not respond to the initial antirejection therapy. Renal-allograft recipients with a failed allograft within six months after the episode of acute rejection had significantly lower FOXP3 mRNA levels in their urinary cells than the 26 subjects who had a functioning allograft (2.0±0.8 and 4.5±0.5, respectively; P=0.01). In the two groups, the levels of mRNA for CD25 (6.6±0.7 and 7.1±0.5, P=0.33), CD3ε (7.9±0.7 and 8.3±0.5, P=0.76), and perforin (7.8±0.6 and 7.6±0.5, P=0.90) did not predict allograft loss.
The rate of and relative risk of graft failure within six months after an episode of acute rejection, for thirds of each mRNA measure, are shown in Figure 4Figure 4
Relative Risk (RR) of Graft Failure after an Episode of Acute Rejection.. At the highest third of FOXP3 mRNA levels, the graft failure rate was 8 percent; at the middle third, the graft failure rate was 25 percent and the relative risk was 3; and at the lowest third, the graft failure rate was 50 percent and the relative risk was 6 (P=0.02 by the chi-square test for linear trend) (Figure 4A). In contrast, the rate of graft failure after an episode of acute rejection did not differ significantly across the thirds of mRNA levels for CD25, CD3ε, and perforin (Figure 4B, Figure 4C, and Figure 4D).Graft failure as compared with graft success was not predicted by the subjects' age (mean [±SD] ages, 39±4.2 years and 42±2.4 years, respectively; P=0.52), sex (4 men and 6 women vs. 11 men and 15 women, P=0.90), race (3 white, 6 black, and 1 with other race or ethnic background vs. 10 white, 6 black, and 10 with other race or ethnic background; P=0.08), graft-donor source (5 living and 5 deceased vs. 15 living and 11 deceased, P=0.68), Banff histologic grade (5 with IA and 5 with >IA vs. 11 with IA and 15 with >IA, P=0.68), or initial antirejection treatment (24 with glucocorticoids and 2 with antilymphocyte antibodies vs. 7 with glucocorticoids and 3 with antilymphocyte antibodies, P=0.12). In subjects with graft failure, as compared with subjects with graft success, serum creatinine levels (median levels, 6.5 mg per deciliter [574.6 μmol per liter] and 2.3 mg per deciliter [203.3 μmol per liter], respectively; P<0.001) and the time from kidney transplantation to the development of acute rejection (median time, 562 days and 82 days; P=0.003) were significantly greater. In a logistic-regression analysis, FOXP3 mRNA levels became nonsignificant after control for serum creatinine levels (P=0.13) or time between transplantation and rejection (P=0.09).
A linear combination of levels of FOXP3 mRNA and creatinine was a better predictor of graft failure (90 percent sensitivity and 92 percent specificity) than were either FOXP3 mRNA levels alone (80 percent sensitivity and 69 percent specificity) or serum creatinine levels alone (85 percent sensitivity and 90 percent specificity).
FOXP3 mRNA Levels and Time to Acute Rejection
Late acute rejection (acute rejection occurring at least three months after transplantation) results in an outcome that is inferior to that of early acute rejection.26,27 We found a strong inverse relationship between levels of FOXP3 mRNA in urinary cells and the time from kidney transplantation to the development of acute rejection (rs=–0.42, P=0.01) (Figure 5AFigure 5
Levels of mRNA in Urinary Cells and the Time from Kidney Transplantation to the Development of Acute Rejection.). Levels of FOXP3 mRNA in urinary cells were lower in 11 urine specimens from patients with late acute rejection than in 25 specimens from patients with early acute rejection (mean [±SE] level, 2.5±0.6 and 4.7±0.5; P=0.009). CD25 mRNA levels also showed an inverse relation (rs=–0.45, P=0.006) (Figure 5B), and the levels were lower during late rejection than during early acute rejection (5.8±0.8 and 7.4±0.4, P=0.07). There was no inverse relation between the time from kidney transplantation to the development of acute rejection and the mRNA levels of CD3ε (rs=–0.26, P=0.12) (Figure 5C) or perforin (rs=–0.02, P=0.91) (Figure 5D). There was also no correlation between the serum creatinine levels at the time of acute rejection and the time from kidney transplantation to the development of acute rejection (rs=0.23, P=0.17).Discussion
Previous studies have associated acute allograft rejection with cytotoxic T cells and have shown that monitoring the levels of these cells in blood, urine, or both is helpful in the treatment of renal-allograft recipients.11,28,29 Our study suggests that levels of FOXP3 mRNA in urinary cells may serve as a mechanistically informative biomarker of acute-rejection outcome.
Depletion or dysfunction of Treg cells can result in autoimmune disease; tolerance to experimental allografts, on the other hand, is associated with graft infiltration by Treg cells.14-16,21-23 An attractive hypothesis is that the Treg cells prevent the emergence of effector T cells, and that the absence of disease or tolerance is due to the lack of an immune response. An alternative hypothesis is that Treg cells play a “damage control” role rather than a preventive one.30 We suggest that the host antidonor immune repertoire during acute rejection includes the activation of graft-destructive effector cells as well as graft-protective Treg cells. We observed that levels of FOXP3 mRNA in urinary cells, a defining functional marker of Treg cells, and mRNA for perforin, a cytotoxic effector, are both expressed in a heightened fashion during acute rejection and that high levels of FOXP3 mRNA are associated with reversible acute rejection and a lower risk of graft failure. These findings are consistent with the hypothesis that Treg cells serve to limit antiallograft immunity and that the lack of counterregulation by Treg cells during an episode of acute rejection results in unrestrained effector-cell activity, impaired allograft function, and even graft failure.
Histologic analysis of renal allografts is considered to be the best predictor of acute rejection.7,8 However, it has long been recognized that cellular interstitial infiltration is not invariably associated with allograft dysfunction or failure.31 In the current study, Banff grades of acute rejection did not predict rejection outcome, and the serum creatinine levels did not vary across Banff grades. We suggest that graft-infiltrating cells comprise both graft-destructive cells such as cytotoxic T cells and graft-protective FOXP3-expressing Treg cells and that graft dysfunction and response to therapy may be predicted more accurately when the heterogeneous nature of the cellular components is better resolved.
Elevated levels of serum creatinine are an established risk factor for renal allograft failure32 and in our studies were shown to be a strong predictor of the outcome of acute rejection. Do levels of FOXP3 mRNA in urinary cells provide information above and beyond that provided by serum creatinine levels? In our study, levels of serum creatinine and FOXP3 mRNA in urinary cells were independent predictors of reversal of acute rejection. Moreover, rejection reversal and graft loss were predicted with a higher degree of accuracy with the use of levels of both FOXP3 mRNA and creatinine than with either one alone. However, since our estimates of sensitivity and specificity were calculated from the same sample that was used to select the cutoff points, the estimates are upwardly biased and need to be reevaluated in an independent sample.
In both adult and pediatric recipients of renal allografts, an episode of late acute rejection is associated with a lower rate of graft survival than an episode of early acute rejection.26,27 Our finding of an inverse relationship between levels of FOXP3 mRNA in urinary cells and the time to acute rejection suggests a cellular mechanism for the hitherto unexplained poor outcome associated with late acute rejection.
A mechanistic hypothesis engendered by our study is that drugs that enhance the generation of Treg cells, or the administration of Treg cells themselves, may improve the outcome of acute rejection. Cyclosporine and tacrolimus both inhibit the production of interleukin-2, an essential growth factor for Treg cells,33 but induce the production of transforming growth factor β1,34,35 an inducer of FOXP3 and a promoter of the development of CD4+CD25+ Treg cells.36,37 Sirolimus (rapamycin) has been shown to promote the expansion of murine Treg cells in vitro,38 and glucocorticoids have been reported to increase the expression of FOXP3 mRNA in human CD4+ cells.39 However, the in vivo effects of drugs on the induction, expansion, and function of Treg cells in allograft recipients remain to be fully characterized.
How might FOXP3-expressing Treg cells exert their salutary activity during an episode of acute rejection? Treg cells have been shown to dampen or suppress local host immune responses by acting on antigen-presenting cells, directly modulating effector-cell functions, or both.14,15 Mechanisms of immunosuppression by FOXP3-expressing Treg cells include direct cell contact, cytokine signaling, and inhibition of transcription of genes central to effector functions.40 The role of these mechanisms in mitigating the acute-rejection response remains undetermined.
In sum, our study suggests that levels of FOXP3 mRNA in urinary cells may serve as a mechanistically informative biomarker of acute-rejection outcome, with lower levels associated with irreversible acute rejection and even graft failure. In addition to suggesting a robust cellular mechanism for the clinically important differences in the outcome of acute-rejection episodes, the strategy we present here may ultimately lead to individualized treatment of renal-allograft recipients and inform antirejection therapy, including the consideration of infusion of Treg cells to treat acute rejection of allografts.
Supported in part by awards (AI51652 and AI60706, to Dr. Suthanthiran, and AI54720, to Dr. Hancock) from the National Institutes of Health, from the International Society of Nephrology (to Dr. Naqvi), and from the American Society of Transplantation (to Dr. Lee).
A U.S. patent entitled “Methods of Evaluating Transplant Rejection” (6187534) was issued on February 13, 2001; Dr. Suthanthiran is one of the inventors. The patent is owned jointly by Harvard Medical School, Cornell University, and the Beth Israel–Deaconess Medical Center, Boston.
We are indebted to Dr. Phyllis August for her careful review of this article and to Linda Stackhouse for her assistance in the preparation of the manuscript.
Source Information
From the Division of Nephrology, Departments of Medicine (T.M., D.D., R.D., C.S., R.N., J.B.L., C.H., B.L., V.K.S., M.S.), Pathology (S.V.S.), and Surgery (S.K.), Weill Medical College of Cornell University; the Department of Transplantation Medicine, New York Presbyterian Hospital–Weill Cornell Medical Center (D.D., C.H., S.K., M.S.); and the Rogosin Institute (D.D., C.H., V.K.S.) — all in New York; the Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia (W.W.H.); and the Department of Psychiatry, State University of New York at Stony Brook, Stony Brook (J.E.S.).
Address reprint requests to Dr. Suthanthiran at the Division of Nephrology and Department of Transplantation Medicine, 525 E. 68th St., Box 3, New York, NY 10021, or at msuthan@med.cornell.edu.
- References
References
1
Langone AJ ,Helderman JH . Disparity between solid-organ supply and demand. N Engl J Med 2003;349:704-706
Full Text | Web of Science | Medline2
Agodoa L ,Eknoyan G ,Ingelfinger J , et al. Assessment of structure and function in progressive renal disease. Kidney Int 1997;63:Suppl:S144-S1503
Cheigh JS ,Saal SD ,Suthanthiran M , et al. Natural history of cadaveric kidney transplants in the absence of early acute rejection. Nephron 1983;35:6-10
CrossRef | Medline4
Gulanikar AC ,MacDonald AS ,Sungurtekin U ,Belitsky P . The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992;53:323-328
CrossRef | Web of Science | Medline5
Hariharan S ,Johnson CP ,Bresnahan BA ,Taranto SE ,McIntosh MJ ,Stablein D . Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-612
Full Text | Web of Science | Medline6
Opelz G . Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipients: the Collaborative Transplant Study. Transplant Proc 1997;29:73-76
CrossRef | Web of Science | Medline7
Matas AJ ,Sibley R ,Mauer M ,Sutherland DE ,Simmons RL ,Najarian JS . The value of needle renal allograft biopsy. I. A retrospective study of biopsies performed during putative rejection episodes. Ann Surg 1983;197:226-237
CrossRef | Web of Science | Medline8
Hayry P . Pathology makes a difference. Transplantation 2000;69:1038-1040
CrossRef | Web of Science | Medline9
Huraib S ,Goldberg H ,Katz A , et al. Percutaneous needle biopsy of the transplanted kidney: technique and complications. Am J Kidney Dis 1989;14:13-17
Web of Science | Medline10
Beckingham IJ ,Nicholson ML ,Bell PR . Analysis of factors associated with complications following renal transplant needle core biopsy. Br J Urol 1994;73:13-15
CrossRef | Medline11
Li B ,Hartono C ,Ding RC , et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001;344:947-954
Full Text | Web of Science | Medline12
Ding R ,Li B ,Muthukumar T , et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 2003;75:1307-1312
CrossRef | Web of Science | Medline13
Tatapudi RR ,Muthukumar T ,Dadhania D , et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004;65:2390-2397
CrossRef | Web of Science | Medline14
Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352
CrossRef | Web of Science | Medline15
Schwartz RH . Natural regulatory T cells and self-tolerance. Nat Immunol 2005;6:327-330
CrossRef | Web of Science | Medline16
Fontenot JD ,Gavin MA ,Rudensky AY . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336
CrossRef | Web of Science | Medline17
Wildin RS ,Ramsdell F ,Peake J , et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001;27:18-20
CrossRef | Web of Science | Medline18
Bennett CL ,Christie J ,Ramsdell F , et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001;27:20-21
CrossRef | Web of Science | Medline19
Brunkow ME ,Jeffery EW ,Hjerrild KA , et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001;27:68-73
CrossRef | Web of Science | Medline20
Khattri R ,Cox T ,Yasayko SA ,Ramsdell F . An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003;4:337-342
CrossRef | Web of Science | Medline21
Graca L ,Cobbold SP ,Waldmann H . Identification of regulatory T cells in tolerated allografts. J Exp Med 2002;195:1641-1646
CrossRef | Web of Science | Medline22
Zheng XX ,Sanchez-Fueyo A ,Sho M ,Domenig C ,Sayegh MH ,Strom TB . Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003;19:503-514
CrossRef | Web of Science | Medline23
Lee I ,Wang L ,Wells AD ,Dorf ME ,Ozkaynak E ,Hancock WW . Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends upon the CCR4 chemokine receptor. J Exp Med 2005;201:1037-1044
CrossRef | Web of Science | Medline24
Racusen LC ,Solez K ,Colvin RB , et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723
CrossRef | Web of Science | Medline25
Helsel DR . Less than obvious -- statistical treatment of data below the detection limit. Environ Sci Technol 1990;24:1766-1774
CrossRef | Web of Science26
Tejani AH ,Stablein DM ,Sullivan EK , et al. The impact of donor source, recipient age, pre-operative immunotherapy and induction therapy on early and late acute rejections in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1998;2:318-324
Medline27
Sijpkens YW ,Doxiadis H ,Mallat MJ , et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2003;75:204-208
CrossRef | Web of Science | Medline28
Strom TB ,Tilney NL ,Carpenter CB ,Busch GJ . Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med 1975;292:1257-1263
Full Text | Web of Science | Medline29
Vasconcellos LM ,Schachter AD ,Zheng XX , et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998;66:562-566
CrossRef | Web of Science | Medline30
Gonzalez A ,Andre-Schmutz I ,Carnaud C ,Mathis D ,Benoist C . Damage control, rather than unresponsiveness, effected by protective DX5+ T cells in autoimmune diabetes. Nat Immunol 2001;2:1117-1125
CrossRef | Web of Science | Medline31
Burdick JF ,Berschorner WE ,Smith WJ , et al. Characteristics of early routine renal allograft biopsies. Transplantation 1984;38:679-684
CrossRef | Web of Science | Medline32
Siddiqi N ,McBride MA ,Hariharan S . Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 2004;65:1906-1913
CrossRef | Web of Science | Medline33
Almeida AR ,Legrand N ,Papiernik M ,Freitas AA . Homeostasis of peripheral CD4+ T cells: IL-2Rα and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002;169:4850-4860
Web of Science | Medline34
Li B ,Sehajpal PK ,Khanna A , et al. Differential regulation of transforming growth factor beta and interleukin 2 genes in human T cells: demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 1991;174:1259-1262
CrossRef | Web of Science | Medline35
Maluccio M ,Sharma V ,Lagman M , et al. Tacrolimus enhances transforming growth factor-beta1 expression and tumor progression in a dose-dependent fashion. Transplantation 2003;76:597-602
CrossRef | Web of Science | Medline36
Chen W ,Jin W ,Hardegen N , et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886
CrossRef | Web of Science | Medline37
Luo X ,Yang H ,Kim IS , et al. Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005;79:1091-1096
CrossRef | Web of Science | Medline38
Battaglia M ,Stabilini A ,Roncarolo MG . Rapamycin selectively expands CD4+ CD25+FoxP3+ regulatory T cells. Blood 2005;105:4743-4748
CrossRef | Web of Science | Medline39
Karagiannidis C ,Akdis M ,Holopainen P , et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004;114:1425-1433
CrossRef | Web of Science | Medline40
von Boehmer H . Mechanisms of suppression by suppressor T cells. Nat Immunol 2005;6:338-344
CrossRef | Web of Science | Medline
- Citing Articles (184)
Citing Articles
1
P. García-Roca, Y. A. Vargas, Y. Fuentes, A. M. Hernández, L. Ortiz, S. Valverde, L. Velásquez-Jones, B. Romero-Navarro, G. Ramón-Garcia, M. Medeiros. (2012) Serum soluble interleukin 2 receptor (sIL-2R) as a marker of acute rejection in renal transplant children. Pediatric Transplantationno-no
CrossRef2
Y. Xu, J. Jin, H. Wang, Z. Shou, J. Wu, F. Han, Q. He, J. Zhao, Y. Bi, J. Chen. (2012) The regulatory/cytotoxic infiltrating T cells in early renal surveillance biopsies predicts acute rejection and survival. Nephrology Dialysis Transplantation
CrossRef3
Winfred W. Williams, Diana Taheri, Nina Tolkoff-Rubin, Robert B. Colvin. (2012) Clinical role of the renal transplant biopsy. Nature Reviews Nephrology
CrossRef4
Georgios Tzimagiorgis, Evangelia Z. Michailidou, Aristidis Kritis, Anastasios K. Markopoulos, Sofia Kouidou. (2011) Recovering circulating extracellular or cell-free RNA from bodily fluids. Cancer Epidemiology 35:6, 580-589
CrossRef5
Y. Luo, B. Shi, Y. Qian, H. Bai, J. Chang. (2011) Sequential Monitoring of TIM-3 Gene Expression in Peripheral Blood for Diagnostic and Prognostic Evaluation of Acute Rejection in Renal Graft Recipients. Transplantation Proceedings 43:10, 3669-3674
CrossRef6
Stephan W. Reinhold, Rainer H. Straub, Bernd Krüger, Bernhard Kaess, Tobias Bergler, Christian Weingart, Miriam C. Banas, Bernhard K. Krämer, Bernhard Banas. (2011) Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2weeks after transplantation. Cytokine
CrossRef7
David W. Mathes, Billanna Hwang, Scott S. Graves, James Edwards, Jeff Chang, Barry E. Storer, Tiffany Butts-Miwongtum, George E. Sale, Richard A. Nash, Rainer Storb. (2011) Tolerance to Vascularized Composite Allografts in Canine Mixed Hematopoietic Chimeras. Transplantation1
CrossRef8
Yi-Tian Ting, P. Toby Coates, Robert J. Walker, Alexander D. McLellan. (2011) Urinary tubular biomarkers as potential early predictors of renal allograft rejection. Nephrologyno-no
CrossRef9
M. J. Scian, D. G. Maluf, K. G. David, K. J. Archer, J. L. Suh, A. R. Wolen, M. U. Mba, H. D. Massey, A. L. King, T. Gehr, A. Cotterell, M. Posner, V. Mas. (2011) MicroRNA Profiles in Allograft Tissues and Paired Urines Associate With Chronic Allograft Dysfunction With IF/TA. American Journal of Transplantation 11:10, 2110-2122
CrossRef10
Kenneth A Newell, Deborah Phippard, Laurence A Turka. (2011) Regulatory cells and cell signatures in clinical transplantation tolerance. Current Opinion in Immunology 23:5, 655-659
CrossRef11
Brian J Nankivell, Dirk RJ Kuypers. (2011) Diagnosis and prevention of chronic kidney allograft loss. The Lancet 378:9800, 1428-1437
CrossRef12
Douglas Thompson, Willem Develter, David A. Cairns, Jennifer H. Barrett, David A. Perkins, Anthea J. Stanley, Andrew Mooney, Peter J. Selby, Rosamonde E. Banks. (2011) A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease. PROTEOMICS - Clinical Applications 5:9-10, 523-531
CrossRef13
Nada Alachkar. (2011) Serum and urinary biomarkers in acute kidney transplant rejection. Néphrologie & Thérapeutique
CrossRef14
Eric A. F. Simões, Kuswandewi Mutyara, Shirlena Soh, Dwi Agustian, Martin L. Hibberd, Cissy B. Kartasasmita. (2011) The Epidemiology of Respiratory Syncytial Virus Lower Respiratory Tract Infections in Children Less than 5 Years of Age in Indonesia. The Pediatric Infectious Disease Journal 30:9, 778-784
CrossRef15
Huimin Fan, Peng Cao, David S. Game, Francesco Dazzi, Zhongmin Liu, Shuiping Jiang. (2011) Regulatory T cell therapy for the induction of clinical organ transplantation tolerance. Seminars in Immunology
CrossRef16
Claus Dieter Dummer, Virna Nowotny Carpio, Luiz Felipe Santos Gonçalves, Roberto Ceratti Manfro, Francisco Veríssimo Veronese. (2011) FOXP3+ regulatory T cells: From suppression of rejection to induction of renal allograft tolerance. Transplant Immunology
CrossRef17
André Hoerning, Kerith Koss, Dipak Datta, Leonard Boneschansker, Caroline N. Jones, Ian Y. Wong, Daniel Irimia, Katiana Calzadilla, Fanny Benitez, Peter F. Hoyer, William E. Harmon, David M. Briscoe. (2011) Subsets of human CD4+ regulatory T cells express the peripheral homing receptor CXCR3. European Journal of Immunology 41:8, 2291-2302
CrossRef18
Birgit Sawitzki, Stephan Schlickeiser, Petra Reinke, Hans-Dieter Volk. (2011) Monitoring tolerance and rejection in organ transplant recipients. Biomarkers 16:S1, S42-S50
CrossRef19
Diana Vavrincova-Yaghi, Leo E. Deelman, Harry Goor, Marc Seelen, Ido P. Kema, Annemieke Smit-van Oosten, Dick Zeeuw, Robert H. Henning, Maria Sandovici. (2011) Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. The Journal of Gene Medicine 13:7-8, 373-381
CrossRef20
Jussi O. Ropponen, Simo O. Syrjälä, Rainer Krebs, Antti Nykänen, Jussi M. Tikkanen, Karl B. Lemström. (2011) Innate and adaptive immune responses in obliterative airway disease in rat tracheal allografts. The Journal of Heart and Lung Transplantation 30:6, 707-716
CrossRef21
Petra Zürbig, Hassan Dihazi, Jochen Metzger, Visith Thongboonkerd, Antonia Vlahou. (2011) Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications. PROTEOMICS - Clinical Applications 5:5-6, 256-268
CrossRef22
Vikas R. Dharnidharka, Sushil Gupta, Eihab Al Khasawneh, Allah Haafiz, Jonathan J. Shuster, Douglas W. Theriaque, Amir H. Shahlaee, Timothy J. Garrett. (2011) Immune biomarker panel monitoring utilizing IDO enzyme activity and CD4 ATP levels: Prediction of acute rejection vs. viral replication events. Pediatric Transplantation 15:3, 321-328
CrossRef23
Bohdan Pomahac, Daniel Nowinski, J. Rodrigo Diaz-Siso, Ericka M. Bueno, Simon G. Talbot, Indranil Sinha, Tormod S. Westvik, Raj Vyas, Dhruv Singhal. (2011) Face Transplantation. Current Problems in Surgery 48:5, 293-357
CrossRef24
Minmin Wang, Qiu Jin, Haiyan Tu, Youying Mao, Jiekai Yu, Ying Chen, Zhangfei Shou, Qiang He, Jianyong Wu, Shu Zheng, Jianghua Chen. (2011) Detection of renal allograft dysfunction with characteristic protein fingerprint by serum proteomic analysis. International Urology and Nephrology
CrossRef25
You-ying Mao, Hao yang, Minmin Wang, Wenhan Peng, Qiang He, Zhang-fei Shou, Hua Jiang, Jianyong Wu, Yong-qi Fang, Hai-tao Dong, Jiang-hua Chen. (2011) Feasibility of diagnosing renal allograft dysfunction by oligonucleotide array: Gene expression profile correlates with histopathology. Transplant Immunology 24:3, 172-180
CrossRef26
P. Grimbert, V. Audard, C. Diet, M. Matignon, A. Plonquet, H. Mansour, D. Desvaux, A. Durrbach, J. L. Cohen, P. Lang. (2011) T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrology Dialysis Transplantation 26:3, 1087-1093
CrossRef27
David C. Neujahr, Christian P. Larsen. (2011) Regulatory T cells in lung transplantation—an emerging concept. Seminars in Immunopathology 33:2, 117-127
CrossRef28
Sophie Brouard, Magali Giral, Jean-Paul Soulillou, Joanna Ashton-Chess. (2011) Elaboration of Gene Expression-Based Clinical Decision Aids for Kidney Transplantation: Where Do We Stand?. Transplantation1
CrossRef29
Petra Hribova, Ondrej Viklicky. (2011) Molecular Phenotypes of Kidney Graft Rejection. Kidney and Blood Pressure Research 34:4, 291-298
CrossRef30
Minnie M. Sarwal, Jacqueline Benjamin, Atul J. Butte, Mark M. Davis, Kathryn Wood, Jeremy Chapman. (2011) Transplantomics and Biomarkers in Organ Transplantation: A Report From the First International Conference. Transplantation1
CrossRef31
Juan Shan, Yinjia Guo, Lei Luo, Jun Lu, Chengwen Li, Chuntao Zhang, Yuchuan Huang, Li Feng, Wenqiao Wu, Dan Long, Shengfu Li, Youping Li. (2011) Do CD4+Foxp3+ Treg cells correlate with transplant outcomes: A systematic review on recipients of solid organ transplantation. Cellular Immunology 270:1, 5-12
CrossRef32
Alberto Sánchez–Fueyo, Terry B. Strom. (2011) Immunologic Basis of Graft Rejection and Tolerance Following Transplantation of Liver or Other Solid Organs. Gastroenterology 140:1, 51-64.e2
CrossRef33
Hye Ryoun Jang, Hamid Rabb. 2011. T-cell Contribution to Injury and Regenerative Processes in Kidney Diseases: Focus on Regulatory T Cells. , 141-150.
CrossRef34
Alkesh Jani. 2011. Biomarkers in Kidney Transplantation. , 233-290.
CrossRef35
David Wojciechowski, Flavio Vincenti. (2010) How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept. Current Opinion in Organ Transplantation 15:6, 697-702
CrossRef36
Fadi Issa, Kathryn J Wood. (2010) CD4+ regulatory T cells in solid organ transplantation. Current Opinion in Organ Transplantation 15:6, 757-764
CrossRef37
Birgit Sawitzki, Petra Reinke, Andreas Pascher, Hans-Dieter Volk. (2010) State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. Current Opinion in Organ Transplantation 15:6, 691-696
CrossRef38
Cheguevara Afaneh, Thangamani Muthukumar, Michelle Lubetzky, Ruchuang Ding, Catherine Snopkowski, Vijay K. Sharma, Surya Seshan, Darshana Dadhania, Joseph E. Schwartz, Manikkam Suthanthiran. (2010) Urinary Cell Levels of mRNA for OX40, OX40L, PD-1, PD-L1, or PD-L2 and Acute Rejection of Human Renal Allografts. Transplantation 90:12, 1381-1387
CrossRef39
Kumiko Isse, Kedar Grama, Isaac Morse Abbott, Andrew Lesniak, John G. Lunz, William M.F. Lee, Susan Specht, Natasha Corbitt, Yoshiaki Mizuguchi, Badrinath Roysam, A.J. Demetris. (2010) Adding Value to Liver (and Allograft) Biopsy Evaluation Using a Combination of Multiplex Quantum Dot Immunostaining, High-Resolution Whole-Slide Digital Imaging, and Automated Image Analysis. Clinics in Liver Disease 14:4, 669-685
CrossRef40
Renaud Snanoudj, Julien Zuber, Christophe Legendre. (2010) Co-Stimulation Blockade as a New Strategy in Kidney Transplantation. Drugs 70:16, 2121-2131
CrossRef41
Schwartz, Robert S., , Nankivell, Brian J., Alexander, Stephen I., . (2010) Rejection of the Kidney Allograft. New England Journal of Medicine 363:15, 1451-1462
Full Text42
Carla C. Baan. (2010) iTregs by vitamins: commentary on ‘Retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 in the presence of TGF-β’. Transplant International 23:10, 984-985
CrossRef43
Caroline B. Madsen, Astrid Nørgaard, Martin Iversen, Lars P. Ryder. (2010) Elevated mRNA levels of CTLA-4, FoxP3, and Granzyme B in BAL, but not in blood, during acute rejection of lung allografts. Transplant Immunology 24:1, 26-32
CrossRef44
W M Freeman, G V Bixler, R M Brucklacher, C-M Lin, K M Patel, H D VanGuilder, K F LaNoue, S R Kimball, A J Barber, D A Antonetti, T W Gardner, S K Bronson. (2010) A multistep validation process of biomarkers for preclinical drug development. The Pharmacogenomics Journal 10:5, 385-395
CrossRef45
Eric A. Elster, Jason S. Hawksworth, Orlena Cheng, David B. Leeser, Michael Ring, Douglas K. Tadaki, David E. Kleiner, John S. Eberhardt, Trevor S. Brown, Roslyn B. Mannon. (2010) Probabilistic (Bayesian) Modeling of Gene Expression in Transplant Glomerulopathy. The Journal of Molecular Diagnostics 12:5, 653-663
CrossRef46
H. Reyes, A. M. Hernández, S. Valverde, A. Cataneo, A. Mendoza, I. Barrera, L. Ortíz, P. García-Roca, B. Lopéz-Martínez, G. Castañeda-Hernández, M. Medeiros. (2010) Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. Pediatric Transplantation 14:6, 746-752
CrossRef47
Simo O. Syrjälä, Mikko A.I. Keränen, Raimo Tuuminen, Antti I. Nykänen, Markku Tammi, Rainer Krebs, Karl B. Lemström. (2010) Increased Th17 rather than Th1 alloimmune response is associated with cardiac allograft vasculopathy after hypothermic preservation in the rat. The Journal of Heart and Lung Transplantation 29:9, 1047-1057
CrossRef48
James N. Fleming, Nicole A. Weimert. (2010) Novel Strategies for Immune Monitoring in Kidney Transplant Recipients. Advances in Chronic Kidney Disease 17:5, e63-e77
CrossRef49
Sangeeta M. Bhorade, Hong Chen, Luciana Molinero, Chuanhong Liao, Edward R. Garrity, Wickii T. Vigneswaran, Rebecca Shilling, Anne Sperling, Anita Chong, Maria-Luisa Alegre. (2010) Decreased Percentage of CD4+FoxP3+ Cells in Bronchoalveolar Lavage From Lung Transplant Recipients Correlates With Development of Bronchiolitis Obliterans Syndrome. Transplantation 90:5, 540-546
CrossRef50
K. L. Pothoven, T. Kheradmand, Q. Yang, J. L. Houlihan, H. Zhang, M. DeGutes, S. D. Miller, X. Luo. (2010) Rapamycin-Conditioned Donor Dendritic Cells Differentiate CD4+CD25+Foxp3+ T Cells In Vitro with TGF-β1 for Islet Transplantation. American Journal of Transplantation 10:8, 1774-1784
CrossRef51
Oriol Bestard, Josep M Cruzado, Marcel la Franquesa, Josep M Grinyó. (2010) Biomarkers in renal transplantation. Current Opinion in Organ Transplantation 15:4, 467-473
CrossRef52
Dorottya Németh, Jörg Ovens, Gerhard Opelz, Claudia Sommerer, Bernd Döhler, Luis E. Becker, Marie-Luise Gross, Rüdiger Waldherr, Markus Mieth, Mahmoud Sadeghi, Jan Schmidt, Robert M. Langer, Martin Zeier, Caner Süsal. (2010) Does Borderline Kidney Allograft Rejection Always Require Treatment?. Transplantation 90:4, 427-432
CrossRef53
KATHERINE A BARRACLOUGH, CHRISTINE E STAATZ, NICOLE M ISBEL, STEVEN J MCTAGGART. (2010) Review Article: Review: Pharmacodynamic monitoring of immunosuppression in kidney transplantation. Nephrology 15:5, 522-532
CrossRef54
Vijay S. Gorantla, Stefan Schneeberger, Gerald Brandacher, Robert Sucher, Dong Zhang, W.P. Andrew Lee, Xin Xiao Zheng. (2010) T regulatory cells and transplantation tolerance. Transplantation Reviews 24:3, 147-159
CrossRef55
Darshana Dadhania, Catherine Snopkowski, Ruchuang Ding, Thangamani Muthukumar, Jun Lee, Heejung Bang, Vijay K. Sharma, Surya Seshan, Phyllis August, Sandip Kapur, Manikkam Suthanthiran. (2010) Validation of Noninvasive Diagnosis of BK Virus Nephropathy and Identification of Prognostic Biomarkers. Transplantation 90:2, 189-197
CrossRef56
Kenneth A. Newell, Adam Asare, Allan D. Kirk, Trang D. Gisler, Kasia Bourcier, Manikkam Suthanthiran, William J. Burlingham, William H. Marks, Ignacio Sanz, Robert I. Lechler, Maria P. Hernandez-Fuentes, Laurence A. Turka, Vicki L. Seyfert-Margolis. (2010) Identification of a B cell signature associated with renal transplant tolerance in humans. Journal of Clinical Investigation 120:6, 1836-1847
CrossRef57
Miguel Hueso, Estanis Navarro, Francesc Moreso, Francisco O'Valle, Mercè Pérez-Riba, Raimundo García del Moral, Josep M. Grinyó, Daniel Serón. (2010) Intragraft Expression of the IL-10 Gene Is Up-Regulated in Renal Protocol Biopsies with Early Interstitial Fibrosis, Tubular Atrophy, and Subclinical Rejection. The American Journal of Pathology 176:4, 1696-1704
CrossRef58
F. Vincenti, B. Charpentier, Y. Vanrenterghem, L. Rostaing, B. Bresnahan, P. Darji, P. Massari, G. A Mondragon-Ramirez, M. Agarwal, G. Di Russo, C.-S. Lin, P. Garg, C. P. Larsen. (2010) A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study). American Journal of Transplantation 10:3, 535-546
CrossRef59
Masato Fujiki, Carlos O. Esquivel, Olivia M. Martinez, Samuel Strober, Shinji Uemoto, Sheri M. Krams. (2010) Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4 + CD25 + FoxP3 + T regulatory cells. Liver Transplantation 16:2, 147-154
CrossRef60
Choli Hartono, Thangamani Muthukumar, Manikkam Suthanthiran. (2010) Noninvasive diagnosis of acute rejection of renal allografts. Current Opinion in Organ Transplantation 15:1, 35-41
CrossRef61
Cécile Taflin, Dominique Nochy, Gary Hill, Thierry Frouget, Nathalie Rioux, Jérome Vérine, Patrick Bruneval, Denis Glotz. (2010) Regulatory T Cells in Kidney Allograft Infiltrates Correlate With Initial Inflammation and Graft Function. Transplantation 89:2, 194-199
CrossRef62
Gang Wang, Bonnie Ching-Ha Kwan, Fernand Mac-Moune Lai, Paul Cheung-Lung Choi, Kai-Ming Chow, Philip Kam-Tao Li, Cheuk-Chun Szeto. (2010) Intrarenal Expression of miRNAs in Patients With Hypertensive Nephrosclerosis. American Journal of Hypertension 23:1, 78-84
CrossRef63
Josh Levitsky, Joshua Miller, Joseph Leventhal, Xuemei Huang, Cathy Flaa, Edward Wang, Anat Tambur, Richard K. Burt, Lorenzo Gallon, James M. Mathew. (2009) The Human “Treg MLR”: Immune Monitoring for FOXP3+ T Regulatory Cell Generation. Transplantation 88:11, 1303-1311
CrossRef64
Ruedi K. Braun, Melanie Molitor-Dart, Christopher Wigfield, Zhuzai Xiang, Sean B. Fain, Ewa Jankowska-Gan, Christine M. Seroogy, William J. Burlingham, David S. Wilkes, David D. Brand, Jose Torrealba, Robert B. Love. (2009) Transfer of Tolerance to Collagen Type V Suppresses T-Helper-Cell-17 Lymphocyte-Mediated Acute Lung Transplant Rejection. Transplantation 88:12, 1341-1348
CrossRef65
J. Zuber, A. Brodin-Sartorius, N. Lapidus, N. Patey, M. Tosolini, S. Candon, M. Rabant, R. Snanoudj, C. Panterne, E. Thervet, C. Legendre, L. Chatenoud. (2009) FOXP3-enriched infiltrates associated with better outcome in renal allografts with inflamed fibrosis. Nephrology Dialysis Transplantation 24:12, 3847-3854
CrossRef66
Eva Fritzsching, Pierre Kunz, Birgitta Maurer, Johannes P
schl, Benedikt Fritzsching. (2009) Regulatory T cells and tolerance induction. Clinical Transplantation 23, 10-14
CrossRef67
Elaine Long, Kathryn J. Wood. (2009) Regulatory T Cells in Transplantation: Transferring Mouse Studies to the Clinic. Transplantation 88:9, 1050-1056
CrossRef68
Nina Babel, Petra Reinke, Hans-Dieter Volk. (2009) Lymphocyte markers and prediction of long-term renal allograft acceptance. Current Opinion in Nephrology and Hypertension 18:6, 489-494
CrossRef69
Peter Nickerson. (2009) Post-transplant monitoring of renal allografts: are we there yet?. Current Opinion in Immunology 21:5, 563-568
CrossRef70
Carla C Baan, I Esmé Dijke, Willem Weimar. (2009) Regulatory T cells in alloreactivity after clinical heart transplantation. Current Opinion in Organ Transplantation 14:5, 577-582
CrossRef71
Paolo Cravedi, Roslyn B Mannon. (2009) Noninvasive methods to assess the risk of kidney transplant rejection. Expert Review of Clinical Immunology 5:5, 535-546
CrossRef72
Thijs K. Hendrikx, Jurjen H. L. Velthuis, Mariska Klepper, Eveline van Gurp, Annemarie Geel, Wenda Schoordijk, Carla C. Baan, Willem Weimar. (2009) Monotherapy rapamycin allows an increase of CD4 + CD25 bright+ FoxP3 + T cells in renal recipients. Transplant International 22:9, 884-891
CrossRef73
Daichi Shimbo, Sujith Kuruvilla, Donald Haas, Thomas G Pickering, Joseph E Schwartz, William Gerin. (2009) Preventing misdiagnosis of ambulatory hypertension: algorithm using office and home blood pressures. Journal of Hypertension 27:9, 1775-1783
CrossRef74
Clemens R. Scherzer. (2009) Chipping away at diagnostics for neurodegenerative diseases. Neurobiology of Disease 35:2, 148-156
CrossRef75
David C. Neujahr, Adriana C. Cardona, Onome Ulukpo, Mark Rigby, Andres Pelaez, Allan Ramirez, Anthony A. Gal, Seth D. Force, E Clinton Lawrence, Allan D. Kirk, Christian P. Larsen. (2009) Dynamics of Human Regulatory T Cells in Lung Lavages of Lung Transplant Recipients. Transplantation 88:4, 521-527
CrossRef76
Marcos López-Hoyos, David San Segundo, Gema Fernández-Fresnedo, María José Marín, Victoria González-Martín, Manuel Arias. (2009) Regulatory T Cells in Renal Transplantation and Modulation by Immunosuppression. Transplantation 88:Supplement, S31-S39
CrossRef77
P. Boros, J. S. Bromberg. (2009) Human FOXP3+ Regulatory T Cells in Transplantation. American Journal of Transplantation 9:8, 1719-1724
CrossRef78
Hsin-Yun Sun, Nina Singh. (2009) Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Current Opinion in Infectious Diseases 22:4, 394-402
CrossRef79
Peter Nickel, Oriol Bestard, Hans-Dieter Volk, Petra Reinke. (2009) Diagnostic value of T-cell monitoring assays in kidney transplantation. Current Opinion in Organ Transplantation 14:4, 426-431
CrossRef80
G. Wang, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, B. C.-H. Kwan, K.-M. Chow, P. K.-T. Li, C.-C. Szeto. (2009) Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response. Rheumatology 48:7, 755-760
CrossRef81
T.K. Hendrikx, M. Klepper, Jan IJzermans, W. Weimar, C.C. Baan. (2009) Clinical rejection and persistent immune regulation in kidney transplant patients. Transplant Immunology 21:3, 129-135
CrossRef82
K. L. Womer, B. Kaplan. (2009) Recent Developments in Kidney Transplantation-A Critical Assessment. American Journal of Transplantation 9:6, 1265-1271
CrossRef83
Joanna Ashton-Chess, Magali Giral, Jean-Paul Soulillou, Sophie Brouard. (2009) Using Biomarkers of Tolerance and Rejection to Identify High- and Low-Risk Patients Following Kidney Transplantation. Transplantation 87:Supplement, S95-S99
CrossRef84
Ünsal Yapici, Fréderike J. Bemelman, Cornelis G. Scheepstra, Joris J. T. H. Roelofs, Nike Claessen, Chris van der Loos, Karlijn van Donselaar-van der Pant, Antonia H. M. Bouts, Mirza M. Idu, Ajda T. Rowshani, Ineke J. M. ten Berge, Sandrine Florquin. (2009) Intragraft FOXP3 Protein or mRNA During Acute Renal Allograft Rejection Correlates With Inflammation, Fibrosis, and Poor Renal Outcome. Transplantation 87:9, 1377-1380
CrossRef85
A. Øzbay, C. Tørring, R. Olsen, J. Carstens. (2009) Transcriptional Profiles in Urine During Acute Rejection, Bacteriuria, CMV Infection and Stable Graft Function After Renal Transplantation. Scandinavian Journal of Immunology 69:4, 357-365
CrossRef86
I Esmé Dijke, Sander S. Korevaar, Kadir Caliskan, Aggie H.M.M. Balk, Alex P.W.M. Maat, Willem Weimar, Carla C. Baan. (2009) Inadequate Immune Regulatory Function of CD4+CD25bright+FoxP3+ T Cells in Heart Transplant Patients who Experience Acute Cellular Rejection. Transplantation 87:8, 1191-1200
CrossRef87
D. Anglicheau, V. K. Sharma, R. Ding, A. Hummel, C. Snopkowski, D. Dadhania, S. V. Seshan, M. Suthanthiran. (2009) MicroRNA expression profiles predictive of human renal allograft status. Proceedings of the National Academy of Sciences 106:13, 5330-5335
CrossRef88
J. Carstens, A. Øzbay, C. Tørring, H.E. Hansen. (2009) Intragraft mRNA cytotoxic molecule expression in renal allograft recipients. Transplant Immunology 20:4, 212-217
CrossRef89
Liqing Wang, Ran Tao, Wayne W Hancock. (2009) Using histone deacetylase inhibitors to enhance Foxp3+ regulatory T-cell function and induce allograft tolerance. Immunology and Cell Biology 87:3, 195-202
CrossRef90
Geoff Y Zhang, Min Hu, Yuan Min Wang, Stephen I Alexander. (2009) Foxp3 as a marker of tolerance induction versus rejection. Current Opinion in Organ Transplantation 14:1, 40-45
CrossRef91
Fabien Stenard, Christine Nguyen, Ken Cox, Neeraja Kambham, Dale T. Umetsu, Sheri M. Krams, Carlos O. Esquivel, Olivia M. Martinez. (2009) Decreases in circulating CD4 + CD25 hi FOXP3 + cells and increases in intragraft FOXP3 + cells accompany allograft rejection in pediatric liver allograft recipients. Pediatric Transplantation 13:1, 70-80
CrossRef92
I. E. Dijke, K. Caliskan, M. Klepper, R. de Kuiper, A. H. M. M. Balk, A. P. W. M. Maat, W. Weimar, C. C. Baan. (2009) Donor-specific Immune Regulation by CD8 + Lymphocytes Expanded from Rejecting Human Cardiac Allografts. American Journal of Transplantation 9:2, 397-403
CrossRef93
Guliang Xia, Malathi Shah, Xunrong Luo. (2009) Prevention of allograft rejection by amplification of Foxp3+CD4+CD25+ regulatory T cells. Translational Research 153:2, 60-70
CrossRef94
Bruce M Hall. (2009) The increasing complexity of understanding rejection. Current Opinion in Organ Transplantation 14:1, 1-3
CrossRef95
Thijs K. Hendrikx, Evelien A. F. J. van Gurp, Varsha D. K. D. Sewgobind, Wendy M. Mol, Wenda Schoordijk, Masriska Klepper, Jurjen H. L. Velthuis, Annemarie Geel, Jan N. M. IJzermans, Willem Weimar, Carla C. Baan. (2009) Generation of Donor-Specific Regulatory T-Cell Function in Kidney Transplant Patients. Transplantation 87:3, 376-383
CrossRef96
Ute Eisenberger, Andrea Seifried, Natacha Patey, Andreas Kappeler, Laure-Hélène Noel, Felix J. Frey, Meike Körner. (2009) FoxP3 Positive T Cells in Graft Biopsies From Living Donor Kidney Transplants After Donor-Specific Transfusions. Transplantation 87:1, 138-142
CrossRef97
Joanna Ashton-Chess, Magali Giral, Jean-Paul Soulillou, Sophie Brouard. (2009) Can immune monitoring help to minimize immunosuppression in kidney transplantation?. Transplant International 22:1, 110-119
CrossRef98
Volker Daniel, Gerhard Opelz. (2009) Clinical Relevance of Immune Monitoring in Solid Organ Transplantation. International Reviews of Immunology 28:3-4, 155-184
CrossRef99
Joseph W. Rossano, Susan W. Denfield, Jeffrey J. Kim, Jack F. Price, John L. Jefferies, Jamie A. Decker, E. O'Brian Smith, Sarah K. Clunie, Jeffrey A. Towbin, William J. Dreyer. (2009) Assessment of the Cylex ImmuKnow Cell Function Assay in Pediatric Heart Transplant Patients. The Journal of Heart and Lung Transplantation 28:1, 26-31
CrossRef100
Avrum Gillespie, Iris J Lee. (2008) Biomarkers in renal transplantation. Biomarkers in Medicine 2:6, 603-612
CrossRef101
Roberto C. Manfro, Esther C. Aquino-Dias, Gabriel Joelsons, Aline L. Nogare, Virna N. Carpio, Luiz Felipe S. Gonçalves. (2008) Noninvasive Tim-3 Messenger RNA Evaluation in Renal Transplant Recipients With Graft Dysfunction. Transplantation 86:12, 1869-1874
CrossRef102
Kathryn Brown, Wilson Wong. (2008) Diagnostic Value of Regulatory T Cells: A New Facet of a Much Studied Cell Population. Transplantation 86:11, 1485-1491
CrossRef103
Naoki Satoda, Tsuyoshi Shoji, Yanling Wu, Takuji Fujinaga, Fengshi Chen, Akihiro Aoyama, Ji Tian Zhang, Ayuko Takahashi, Toshihiro Okamoto, Izumi Matsumoto, Hiroaki Sakai, Ying Li, Xiangdong Zhao, Toshiaki Manabe, Eiji Kobayashi, Shimon Sakaguchi, Hiromi Wada, Hidenori Ohe, Shinji Uemoto, Junichi Tottori, Toru Bando, Hiroshi Date, Takaaki Koshiba. (2008) Value of FOXP3 Expression in Peripheral Blood as Rejection Marker After Miniature Swine Lung Transplantation. The Journal of Heart and Lung Transplantation 27:12, 1293-1301
CrossRef104
Michael Eikmans, Dave L Roelen, Frans HJ Claas. (2008) Molecular monitoring for rejection and graft outcome in kidney transplantation. Expert Opinion on Medical Diagnostics 2:12, 1365-1379
CrossRef105
Olaf Boenisch, Anil Chandraker. (2008) Predictive biomarkers of renal allograft failure. Expert Opinion on Medical Diagnostics 2:11, 1279-1290
CrossRef106
A. Jacquet, H. Francois, C. Frangie, L. Ahmad, B. Charpentier, A. Durrbach. (2008) Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation. Transplant Immunology 20:1-2, 29-31
CrossRef107
Herman Waldmann, Elizabeth Adams, Paul Fairchild, Stephen Cobbold. (2008) Regulation and Privilege in Transplantation Tolerance. Journal of Clinical Immunology 28:6, 716-725
CrossRef108
Noora Alakulppi, Paula Seikku, Taina Jaatinen, Christer Holmberg, Jarmo Laine. (2008) Feasibility of Diagnosing Subclinical Renal Allograft Rejection in Children By Whole Blood Gene Expression Analysis. Transplantation 86:9, 1222-1228
CrossRef109
J. A. Bluestone, W. Liu, J. M. Yabu, Z. G. Laszik, A. Putnam, M. Belingheri, D. M. Gross, R. M. Townsend, F. Vincenti. (2008) The Effect of Costimulatory and Interleukin 2 Receptor Blockade on Regulatory T Cells in Renal Transplantation. American Journal of Transplantation 8:10, 2086-2096
CrossRef110
X. Luo, K. L. Pothoven, D. McCarthy, M. DeGutes, A. Martin, D. R. Getts, G. Xia, J. He, X. Zhang, D. B. Kaufman, S. D. Miller. (2008) ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proceedings of the National Academy of Sciences 105:38, 14527-14532
CrossRef111
Hua Zhou, Anita Cheruvanky, Xuzhen Hu, Takayuki Matsumoto, Noriyuki Hiramatsu, Monique E Cho, Alexandra Berger, Asada Leelahavanichkul, Kent Doi, Lakhmir S Chawla, Gabor G Illei, Jeffrey B Kopp, James E Balow, Howard A Austin, Peter S T Yuen, Robert A Star. (2008) Urinary exosomal transcription factors, a new class of biomarkers for renal disease. Kidney International 74:5, 613-621
CrossRef112
Valeriya Zarkhin, Minnie M. Sarwal. (2008) Microarrays: Monitoring for Transplant Tolerance and Mechanistic Insights. Clinics in Laboratory Medicine 28:3, 385-410
CrossRef113
Bruce Swearingen, Kadiyala Ravindra, Hong Xu, Shengli Wu, Warren C. Breidenbach, Suzanne T. Ildstad. (2008) Science of Composite Tissue Allotransplantation. Transplantation 86:5, 627-635
CrossRef114
Asif N. Butt, R. Swaminathan. (2008) Overview of Circulating Nucleic Acids in Plasma/Serum. Annals of the New York Academy of Sciences 1137:1, 236-242
CrossRef115
Darshana Dadhania, Catherine Snopkowski, Ruchuang Ding, Thangamani Muthukumar, Christina Chang, Meredith Aull, Jun Lee, Vijay K. Sharma, Sandip Kapur, Manikkam Suthanthiran. (2008) Epidemiology of BK Virus in Renal Allograft Recipients: Independent Risk Factors for BK Virus Replication. Transplantation 86:4, 521-528
CrossRef116
Rajani Dinavahi, Peter S Heeger. (2008) T-cell immune monitoring in organ transplantation. Current Opinion in Organ Transplantation 13:4, 419-424
CrossRef117
Dany Anglicheau, Manikkam Suthanthiran. (2008) Noninvasive Prediction of Organ Graft Rejection and Outcome Using Gene Expression Patterns. Transplantation 86:2, 192-199
CrossRef118
S. Bunnag, K. Allanach, G. S. Jhangri, B. Sis, G. Einecke, M. Mengel, T. F. Mueller, P. F. Halloran. (2008) FOXP3 Expression in Human Kidney Transplant Biopsies Is Associated with Rejection and Time Post Transplant but Not with Favorable Outcomes. American Journal of Transplantation 8:7, 1423-1433
CrossRef119
I. Esmé Dijke, Willem Weimar, Carla C. Baan. (2008) Regulatory T cells after organ transplantation: Where does their action take place?. Human Immunology 69:7, 389-398
CrossRef120
L. C. Racusen. (2008) T-Regulatory Cells in Human Transplantation. American Journal of Transplantation 8:7, 1359-1360
CrossRef121
Volker Daniel, Cord Naujokat, Mahmoud Sadeghi, Rolf Weimer, Fabrice Renner, Sevgi Yildiz, Gerhard Opelz. (2008) Observational support for an immunoregulatory role of CD3 + CD4 + CD25 + IFN-γ + blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transplant International 21:7, 646-660
CrossRef122
Maria Sandovici, Leo E. Deelman, Dick de Zeeuw, Harry van Goor, Robert H. Henning. (2008) Immune modulation and graft protection by gene therapy in kidney transplantation. European Journal of Pharmacology 585:2-3, 261-269
CrossRef123
V. Kliem, L. Fricke, T. Wollbrink, M. Burg, J. Radermacher, F. Rohde. (2008) Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial. American Journal of Transplantation 8:5, 975-983
CrossRef124
E C Aquino-Dias, G Joelsons, D M da Silva, R H Berdichewski, A R Ribeiro, F J V Veronose, L F Gonçalves, R C Manfro. (2008) Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney International 73:7, 877-884
CrossRef125
Dirk R. J. Kuypers. (2008) Immunosuppressive Drug Therapy and Subclinical Acute Renal Allograft Rejection: Impact and Effect. Transplantation 85:Supplement, S25-S30
CrossRef126
Nicolas Couturier, Jacques P. Zappulla, Valérie Lauwers-Cances, Emmanuelle Uro-Coste, Marie-Bernadette Delisle, Michel Clanet, Lisette Montagne, Paul Van der Valk, Lars Bö, Roland S. Liblau. (2008) Mast cell transcripts are increased within and outside multiple sclerosis lesions. Journal of Neuroimmunology 195:1-2, 176-185
CrossRef127
R. Girlanda, D. E. Kleiner, Z. Duan, E. A. S. Ford, E. C. Wright, R. B. Mannon, A. D. Kirk. (2008) Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection. American Journal of Transplantation 8:3, 600-607
CrossRef128
Lynn D. Cornell, R. Neal Smith, Robert B. Colvin. (2008) Kidney Transplantation: Mechanisms of Rejection and Acceptance. Annual Review of Pathology: Mechanisms of Disease 3:1, 189-220
CrossRef129
Kawai, Tatsuo, Cosimi, A. Benedict, Spitzer, Thomas R., Tolkoff-Rubin, Nina, Suthanthiran, Manikkam, Saidman, Susan L., Shaffer, Juanita, Preffer, Frederic I., Ding, Ruchuang, Sharma, Vijay, Fishman, Jay A., Dey, Bimalangshu, Ko, Dicken S.C., Hertl, Martin, Goes, Nelson B., Wong, Waichi, Williams, Winfred W. Jr., Colvin, Robert B., Sykes, Megan, Sachs, David H., . (2008) HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression. New England Journal of Medicine 358:4, 353-361
Full Text130
Brian J. Nankivell. 2008. Chronic Allograft Nephropathy. , 416-438.
CrossRef131
I. Esmé Dijke, Kadir Caliskan, Sander S. Korevaar, Alex P.W.M. Maat, Pieter E. Zondervan, Aggie H.M.M. Balk, Willem Weimar, Carla C. Baan. (2008) FOXP3 mRNA expression analysis in the peripheral blood and allograft of heart transplant patients. Transplant Immunology 18:3, 250-254
CrossRef132
Sunil Kurian, Yevgeniy Grigoryev, Steve Head, Daniel Campbell, Tony Mondala, Daniel R. Salomon. (2007) Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. International Immunopharmacology 7:14, 1948-1960
CrossRef133
Kathryn Brown, Victoria Moxham, Julieta Karegli, Richard Phillips, Steven H. Sacks, Wilson Wong. (2007) Ultra-Localization of Foxp3+ T Cells within Renal Allografts Shows Infiltration of Tubules Mimicking Rejection. The American Journal of Pathology 171:6, 1915-1922
CrossRef134
Joanna Ashton-Chess, Magali Giral, Sophie Brouard, Jean-Paul Soulillou. (2007) Spontaneous Operational Tolerance After Immunosuppressive Drug Withdrawal in Clinical Renal Allotransplantation. Transplantation 84:10, 1215-1219
CrossRef135
Stavros Garantziotis, Scott M Palmer. (2007) Genetics and genomics in human lung transplantation. Expert Review of Respiratory Medicine 1:2, 271-278
CrossRef136
Cécile Braudeau, Maud Racape, Magali Giral, Stéphanie Louis, Anne Moreau, Laureline Berthelot, Michèle Heslan, Joanna Ashton-Chess, Jean-Paul Soulillou, Sophie Brouard. (2007) Variation in numbers of CD4 + CD25 high FOXP3 + T cells with normal immuno-regulatory properties in long-term graft outcome. Transplant International 20:10, 845-855
CrossRef137
Hans-Dieter Volk. (2007) Predicting tolerance by counting natural regulatory T cells (CD4+25++FoxP+)?. Transplant International 20:10, 842-844
CrossRef138
GANG WANG, CHEUK-CHUN SZETO. (2007) Quantification of gene expression in urinary sediment for the study of renal diseases. Nephrology 12:5, 494-499
CrossRef139
Wilfried Gwinner. (2007) Renal transplant rejection markers. World Journal of Urology 25:5, 445-455
CrossRef140
WENHAN PENG, JIANGHUA CHEN, YUGUANG JIANG, ZHANGFEI SHOU, YING CHEN, HUIPING WANG. (2007) Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. Nephrology 0:0, 070918212946005-???
CrossRef141
M. Sykes. (2007) Immune tolerance: mechanisms and application in clinical transplantation. Journal of Internal Medicine 262:3, 288-310
CrossRef142
Herman Waldmann. (2007) Regulation and privilege in transplantation. Current Opinion in Organ Transplantation 12:4, 340-344
CrossRef143
Elaine Long, Kathryn J. Wood. (2007) Understanding FOXP3: Progress Towards Achieving Transplantation Tolerance. Transplantation 84:4, 459-461
CrossRef144
Raffaele Girlanda, Roslyn B. Mannon, Allan D. Kirk. (2007) Diagnostic Tools for Monitoring Kidney Transplant Recipients. Seminars in Nephrology 27:4, 462-478
CrossRef145
D. San Segundo, M.J. Benito, G. Fernández-Fresnedo, M.J. Marín, M. Arias, M. López-Hoyos, Nicole Thielens. (2007) Células T reguladoras y tolerancia en trasplante: Efecto de la inmunosupresión farmacológica. Inmunología 26:3, 157-168
CrossRef146
S. M. Kang, Q. Tang, J. A Bluestone. (2007) CD4 + CD25 + Regulatory T Cells in Transplantation: Progress, Challenges and Prospects. American Journal of Transplantation 7:6, 1457-1463
CrossRef147
Walter Park, Matthew Griffin, Joseph P. Grande, Fernando Cosio, Mark D. Stegall. (2007) Molecular Evidence of Injury and Inflammation in Normal and Fibrotic Renal Allografts One Year Posttransplant. Transplantation 83:11, 1466-1476
CrossRef148
C. Süsal, G. Opelz. (2007) Options for Immunologic Support of Renal Transplantation Through the HLA and Immunology Laboratories. American Journal of Transplantation 7:6, 1450-1456
CrossRef149
Hua Yang, Ruchuang Ding, Vijay K. Sharma, Fludd Saint Hilaire, Milagros Lagman, Baogui Li, Dolea A. Thomas, Xunrong Luo, Ping Song, Craig Stauffer, Phyllis August, Manikkam Suthanthiran. (2007) Hyperexpression of Foxp3 and IDO During Acute Rejection of Islet Allografts. Transplantation 83:12, 1643-1647
CrossRef150
Robert E. Cirocco, Manuel R. Carre??o, James M. Mathew, Rolando O. Garcia-Morales, Laphalle Fuller, Violet Esquenazi, Gaetano Ciancio, George W. Burke, Jeffrey J. Gaynor, Bonnie B. Blomberg, Anne Rosen, Gary Kleiner, Camillo Ricordi, Joshua Miller. (2007) FoxP3 mRNA Transcripts and Regulatory Cells in Renal Transplant Recipients 10 Years After Donor Marrow Infusion. Transplantation 83:12, 1611-1619
CrossRef151
I Esm?? Dijke, Jurjen H. L. Velthuis, Kadir Caliskan, Sander S. Korevaar, Alex P. W. M. Maat, Pieter E. Zondervan, Aggie H. M. M. Balk, Willem Weimar, Carla C. Baan. (2007) Intragraft FOXP3 mRNA Expression Reflects Antidonor Immune Reactivity in Cardiac Allograft Patients. Transplantation 83:11, 1477-1484
CrossRef152
Stephan Segerer, Detlef Schlöndorff. (2007) Role of Chemokines for the Localization of Leukocyte Subsets in the Kidney. Seminars in Nephrology 27:3, 260-274
CrossRef153
Andrea Augello, Roberta Tasso, Simone Maria Negrini, Ranieri Cancedda, Giuseppina Pennesi. (2007) Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis & Rheumatism 56:4, 1175-1186
CrossRef154
E. O'Riordan, T. N. Orlova, V. N. Podust, P. N. Chander, S. Yanagi, M. Nakazato, R. Hu, K. Butt, V. Delaney, M. S. Goligorsky. (2007) Characterization of Urinary Peptide Biomarkers of Acute Rejection in Renal Allografts. American Journal of Transplantation 7:4, 930-940
CrossRef155
F. Veronese, S. Rotman, R. N. Smith, T. D. Pelle, M. L. Farrell, T. Kawai, A. Benedict Cosimi, R. B. Colvin. (2007) Pathological and Clinical Correlates of FOXP3 + Cells in Renal Allografts during Acute Rejection. American Journal of Transplantation 7:4, 914-922
CrossRef156
Alvaro Pacheco-Silva. (2007) Immune function, as assessed by the ImmuKnow® assay, correlates with clinical outcomes in transplant recipients. Nature Clinical Practice Nephrology 3:4, 196-197
CrossRef157
Ahmet Demirkiran, Carla C. Baan, Alice Kok, Herold J. Metselaar, Hugo W. Tilanus, Luc J. W. van der Laan. (2007) Intrahepatic Detection of FOXP3 Gene Expression After Liver Transplantation Using Minimally Invasive Aspiration Biopsy. Transplantation 83:6, 819-823
CrossRef158
Noora S. Alakulppi, Lauri E. Kyll??nen, Jukka Partanen, Kaija T. Salmela, Jarmo T. Laine. (2007) Diagnosis of Acute Renal Allograft Rejection by Analyzing Whole Blood mRNA Expression of Lymphocyte Marker Molecules. Transplantation 83:6, 791-798
CrossRef159
Philippe Grimbert, Hicham Mansour, D Desvaux, Fran??oise Roudot-Thoraval, Vincent Audard, Karine Dahan, Fran??ois Berrehar, Catherine Dehoulle-Poillet, Jean Pierre Farcet, Philippe Lang, Sabine Le Gouvello. (2007) The Regulatory/Cytotoxic Graft-Infiltrating T Cells Differentiate Renal Allograft Borderline Change From Acute Rejection. Transplantation 83:3, 341-346
CrossRef160
M. Seiler, I. Brabcova, O. Viklicky, P. Hribova, C. Rosenberger, J. Pratschke, A. Lodererova, M. Matz, C. Schönemann, P. Reinke, H.-D. Volk, K. Kotsch. (2007) Heightened Expression of the Cytotoxicity Receptor NKG2D Correlates with Acute and Chronic Nephropathy After Kidney Transplantation. American Journal of Transplantation 7:2, 423-433
CrossRef161
G Brandacher, F Cakar, C Winkler, S Schneeberger, P Obrist, C Bösmüller, G Werner-Felmayer, E R Werner, H Bonatti, R Margreiter, D Fuchs. (2007) Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney International 71:1, 60-67
CrossRef162
R. Dhir. (2007) Messenger RNA for FOXP3 in the Urine of Renal-Allograft Recipients. Yearbook of Pathology and Laboratory Medicine 2007, 200-201
CrossRef163
J.A. Stockman. (2007) Messenger RNA for FOXP3 in the Urine of Renal-Allograft Recipients. Yearbook of Pediatrics 2007, 185-187
CrossRef164
V. Krishnamurthi. (2007) Messenger RNA for FOXP3 in the Urine of Renal-Allograft Recipients. Yearbook of Urology 2007, 54-55
CrossRef165
Maurilio Ponzoni, Gianluigi Arrigoni, Claudio Doglioni. (2007) New Transcription Factors in Diagnostic Hematopathology. Advances in Anatomic Pathology 14:1, 25-35
CrossRef166
Carla C. Baan, Jurjen H.L. Velthuis, Evelien A.F.J. van Gurp, Wendy M. Mol, Mariska Klepper, Jan N.M. Ijzermans, Willem Weimar. (2007) Functional CD25 bright+ alloresponsive T cells in fully immunosuppressed renal allograft recipients. Clinical Transplantation 21:1, 63-71
CrossRef167
F. Meloni, M. Morosini, N. Solari, F. Bini, P. Vitulo, E. Arbustini, C. Pellegrini, A.M. Fietta. (2006) Peripheral CD4+ CD25+ Treg cell expansion in lung transplant recipients is not affected by calcineurin inhibitors. International Immunopharmacology 6:13-14, 2002-2010
CrossRef168
Assia Eljaafari, Lionel Badet, Jean Kanitakis, Christophe Ferrand, Annie Farre, Palmina Petruzzo, Emmanuel Morelon, Muriel Dubosson, Pierre Tiberghien, Val??rie Dubois, Xavier Martin, Pierre Miossec, Jean-Michel Dubernard. (2006) Isolation of Regulatory T Cells in the Skin of a Human Hand-Allograft, Up to Six Years Posttransplantation. Transplantation 82:12, 1764-1768
CrossRef169
Minnie M. Sarwal, Li Li. (2006) Designer Genes: Filling the Gap in Transplantation. Transplantation 82:10, 1261-1272
CrossRef170
A. Franzke, J. K. Hunger, K. E. J. Dittmar, A. Ganser, J. Buer. (2006) Regulatory T-cells in the control of immunological diseases. Annals of Hematology 85:11, 747-758
CrossRef171
Lauren A. Weintraub, Minnie M. Sarwal. (2006) Microarrays: a monitoring tool for transplant patients?. Transplant International 19:10, 775-788
CrossRef172
Stefan Schaub, John A Wilkins, David Rush, Peter Nickerson. (2006) Developing a tool for noninvasive monitoring of renal allografts. Expert Review of Proteomics 3:5, 497-509
CrossRef173
Stephen P. Cobbold, Elizabeth Adams, Luis Graca, Stephen Daley, Stephen Yates, Alison Paterson, Nathan J. Robertson, Kathleen F. Nolan, Paul J. Fairchild, Herman Waldmann. (2006) Immune privilege induced by regulatory T cells in transplantation tolerance. Immunological Reviews 213:1, 239-255
CrossRef174
Douglas A. Hale. (2006) Basic Transplantation Immunology. Surgical Clinics of North America 86:5, 1103-1125
CrossRef175
P H Tan. (2006) World Transplant Congress. Expert Opinion on Biological Therapy 6:10, 1061-1065
CrossRef176
Renaud Snanoudj, Helene de Preneuf, Caroline Creput, Nadia Arzouk, Benjamin Deroure, Severine Beaudreuil, Antoine Durrbach, Bernard Charpentier. (2006) Costimulation blockade and its possible future use in clinical transplantation. Transplant International 19:9, 693-704
CrossRef177
Maria Yannaraki, Jean-Michel Rebibou, Didier Ducloux, Philippe Saas, Anne Duperrier, Sophie Felix, Gerard Rifle, Jean-Marc Chalopin, Patrick Herve, Pierre Tiberghien, Christophe Ferrand. (2006) Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection*. Transplant International 19:9, 759-768
CrossRef178
Qizhi Tang, Jeffrey A. Bluestone. (2006) Regulatory T-cell physiology and application to treat autoimmunity.. Immunological Reviews 212:1, 217-237
CrossRef179
(2006) Urinary FOXP3 Messenger RNA and Renal-Allograft Rejection. New England Journal of Medicine 354:21, 2291-2293
Full Text180
Caroline Ballet, Magali Giral, Joanna Ashton-Chess, Karine Renaudin, Sophie Brouard, Jean-Paul Soulillou. (2006) Chronic rejection of human kidney allografts. Expert Review of Clinical Immunology 2:3, 393-402
CrossRef181
G J Burckart, I V Hutchinson, A Zeevi. (2006) Pharmacogenomics and lung transplantation: clinical implications. The Pharmacogenomics Journal
CrossRef182
Terry B Strom, Manikkam Suthanthiran. (2006) Transcriptional profiling to assess the clinical status of kidney transplants. Nature Clinical Practice Nephrology 2:3, 116-117
CrossRef183
Kate Matthews. (2006) FOXP3 mRNA in the urine of renal allograft recipients predicts outcome of acute rejection. Nature Clinical Practice Nephrology 2:3, 122-123
CrossRef184
Strom, Terry B., . (2005) Rejection — More Than the Eye Can See. New England Journal of Medicine 353:22, 2394-2396
Full Text
- Letters
